About biologic therapeutics
Biologic therapeutics include virus, therapeutic serums, toxins, allergenic products, antitoxin, blood components or derivatives, vaccines, blood, and proteins (except any chemically synthesized polypeptide). They also include analogous products, arsphenamine, or derivatives of arsphenamine (or any other trivalent organic arsenic compound) for the prevention, treatment, or cure of a disease. The differences between the biologics and small molecules include the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics have a higher molecular weight and a complex molecular structure. They are usually derived from living entities, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures (thermolabile) and light.
Technavio's analysts forecast the global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).
Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
Technavio's report, Global Biologic Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global biologic therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Amgen
• F. Hoffmann-La Roche
• Novo Nordisk
• Sanofi
Other prominent vendors
• AbbVie
• AstraZeneca
• Bavarian Nordic
• Baxter International
• Beijing Minhai Biotechnology
• Bharat Biotech
• Bharat Immunologicals and Biologicals
• Bio Med Pvt.
• bioCSL
• Biodel
• Bristol-Myers Squibb
• Diamyd Medical
• DiaVacs
• Dynavax Technologies
• Eli Lilly
• Generex Biotechnology
• Hualan Biological Engineering
• Imunoloski Zavod
• Indian Immunologicals
• Janssen
• JN International Medical
• Kaketsuken
• LG Life Sciences
• Macrogenics
• MannKind
• Merck
• Mitsubishi Tanabe Pharma
• Nuron Biotech
• Osiris Therapeutics
• Pfizer
• Protalix
• Protein Sciences
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• Sinovac Biotech
• Tolerion
• Vacunas Finlay
• XOMA
• Zydus Cadila
Market driver
• Reimbursement support for biologics
• For a full, detailed list, view our report
Market challenge
• High cost of therapy
• For a full, detailed list, view our report
Market trend
• Emergence of targeted and combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by type of molecules
PART 07: Global protein therapeutics market
Introduction
Drivers, challenges, and trends
Market segmentation by type of molecules
PART 08: Global vaccines market
Introduction
Drivers, challenges, and trends
Market segmentation by end-user age group
PART 09: Global cell therapy market
Introduction
Drivers, challenges, and trends
Market size and forecast
PART 10: Geographical segmentation
Biologic therapeutics market in Americas
Biologic therapeutics market in EMEA
Biologic therapeutics market in APAC
PART 11: Market drivers
Reimbursement support for biologics
Promising drug pipeline
Focus on development of novel mechanisms
Increase in industry–academia collaborations
PART 12: Impact of drivers
PART 13: Market challenges
High cost of therapy
Stringent regulatory guidelines
Fierce market competition
Cold chain management
Poor diagnosis and screening
PART 14: Impact of drivers and challenges
PART 15: Market trends
Emergence of targeted and combination therapies
Increase in R&D
Shift in focus to untapped markets
Rise in public awareness
PART 16: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis
Amgen
F. Hoffmann-La Roche
Novo Nordisk
Sanofi
Other and future prominent vendors
PART 17: Key vendor analysis
Amgen
F. Hoffmann-La Roche
Novo Nordisk
Sanofi
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global biologic therapeutics market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global biologic therapeutics market segmentation by type of molecules
Exhibit 05: Global biologic therapeutics market segmentation by type of molecules 2014
Exhibit 06: Global biologic therapeutics market segmentation by type of molecules 2014-2019 ($ billions)
Exhibit 07: Key drivers and challenges of global protein therapeutics market
Exhibit 08: Key trends of global protein therapeutics market
Exhibit 09: Global protein therapeutics market 2014-2019 ($ billions)
Exhibit 10: Global protein therapeutics market 2014
Exhibit 11: Global protein therapeutics market by type of molecules 2014-2019 ($ billions)
Exhibit 12: Global monoclonal antibodies market 2014-2019 ($ billions)
Exhibit 13: Global enzymes market 2014-2019 ($ billions)
Exhibit 14: Global other protein therapeutics market 2014-2019 ($ billions)
Exhibit 15: Drivers of global vaccines market
Exhibit 16: Challenges of global vaccines market
Exhibit 17: Trends in global vaccines market
Exhibit 18: Global vaccines market 2014-2019 ($ billions)
Exhibit 19: Global vaccines market by end-user age group 2014
Exhibit 20: Global vaccines market by end-user age group 2014-2019 ($ billions)
Exhibit 21: Global pediatric vaccines market 2014-2019 ($ billions)
Exhibit 22: Global adult vaccines market 2014-2019 ($ billions)
Exhibit 23: Key factors influencing the global cell therapy market
Exhibit 24: Global cell therapy market 2014-2019 ($ billions)
Exhibit 25: Global biologic therapeutics market by geography 2014
Exhibit 26: Biologic therapeutics market in Americas 2014-2019 ($ billions)
Exhibit 27: Biologic therapeutics market in EMEA 2014-2019 ($ billions)
Exhibit 28: Biologic therapeutics market in APAC 2014-2019 ($ billions)
Exhibit 29: Global biologic therapeutics market by geography 2014-2019 ($ billions)
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Revenue of Enbrel 2012-2014 ($ millions)
Exhibit 33: Revenue of Epogen 2012-2014 ($ millions)
Exhibit 34: Revenue of Neulasta/Neupogen 2012-2014 ($ millions)
Exhibit 35: Revenue of vectibix 2012-2014 ($ millions)
Exhibit 36: Revenue of Xgeva 2012-2014 ($ millions)
Exhibit 37: Revenue of Prolia 2012-2014 ($ millions)
Exhibit 38: Revenue of Avastin 2012-2014 ($ millions)
Exhibit 39: Revenue of Kadcyla 2013 and 2014 ($ millions)
Exhibit 40: Revenue of Lucentis 2012-2014 ($ millions)
Exhibit 41: Revenue of Rituxan/MabThera 2012-2014 ($ millions)
Exhibit 42: Revenue of Pegasys 2012-2014 ($ millions)
Exhibit 43: Revenue of Perjeta 2013 and 2014 ($ millions)
Exhibit 44: Revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 45: Revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 46: Revenue of Apridra 2012-2014 ($ millions)
Exhibit 47: Revenue of Cerezyme 2012-2014 ($ millions)
Exhibit 48: Revenue of Fabrazyme 2012-2014 ($ millions)
Exhibit 49: Revenue of Myozyme/Lumizyme 2012-2014 ($ millions)
Exhibit 50: Revenue of Lantus 2012-2014 ($ millions)
Exhibit 51: Revenue of Zaltrap 2012-2014 ($ millions)
Exhibit 52: Amgen: Business segmentation by revenue 2014
Exhibit 53: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 54: Amgen: Geographical segmentation by revenue 2014
Exhibit 55: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 56: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 57: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 58: Novo Nordisk: R&D expenditure 2014
Exhibit 59: Business segmentation by revenue 2013 and 2014 ($ billions)
